Health Care & Life Sciences » Biotechnology | SIGA Technologies Inc.

SIGA Technologies Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
91,309.80
103,713.90
112,711.00
38,840.70
30,559.10
112,104.90
Total Accounts Receivable
982.00
491.60
3,676.70
3,154.40
1,802.10
1,959.10
Inventories
20,515.30
19,044.50
12,447.10
26,210.00
2,983.20
2,908.20
Other Current Assets
11,134.70
898.70
624.00
954.40
2,020.00
4,317.60
Total Current Assets
123,941.80
124,148.70
129,458.80
69,159.50
37,364.50
121,289.80
Net Property, Plant & Equipment
1,382.10
831.90
449.80
299.50
138.60
171.30
Total Investments and Advances
-
-
1,300.00
17,333.30
6,542.40
68,292
Intangible Assets
898.30
898.30
898.30
898.30
898.30
898.30
Other Assets
24,661.40
34,850.40
53,626.00
73,291.40
97,294.50
1,058.90
Total Assets
193,824.20
172,397.10
204,887.40
187,820.20
167,482.60
203,923.20
ST Debt & Current Portion LT Debt
1,968.80
1,989.90
-
-
-
Accounts Payable
5,064.40
3,384.30
3,944.50
2,517.10
1,328.90
Other Current Liabilities
5,155.80
2,086.00
3,388.60
11,312.20
5,481.60
Total Current Liabilities
12,189.00
7,460.30
7,333.10
13,829.20
6,810.40
Long-Term Debt
1,989.90
-
-
66,553.10
71,050.30
Deferred Taxes
42,940.60
244.50
265.60
286.10
2,432.00
Other Liabilities
162,669.80
399,527.10
462,562.80
367,731.90
389,947.90
Total Liabilities
176,848.80
418,899.50
489,315.90
475,238.50
490,620.90
Common Equity (Total)
16,975.50
246,502.50
284,428.60
287,418.30
323,138.30
Total Shareholders' Equity
16,975.50
246,502.50
284,428.60
287,418.30
323,138.30
Total Equity
16,975.50
246,502.50
284,428.60
287,418.30
323,138.30
Liabilities & Shareholders' Equity
193,824.20
172,397.10
204,887.40
187,820.20
167,482.60

About SIGA Technologies

View Profile
Address
31 East 62nd Street
New York New York 10065
United States
Employees -
Website http://www.siga.com
Updated 07/08/2019
SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand.